Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QEZ | ISIN: US59564R8079 | Ticker-Symbol: 5MP1
NASDAQ
27.06.25 | 19:27
0,892 US-Dollar
-3,20 % -0,030
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIODEXA PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
BIODEXA PHARMACEUTICALS PLC ADR 5-Tage-Chart

Aktuelle News zur BIODEXA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:36Biodexa Pharmaceuticals PLC: Results of Annual General Meeting136June 27, 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing...
► Artikel lesen
MiBiodexa Pharmaceuticals PLC: Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)113June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"),...
► Artikel lesen
MoBiodexa Pharmaceuticals PLC: Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)68June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX),...
► Artikel lesen
18.06.Biodexa enrolls first patient in type 1 diabetes drug trial4
18.06.Biodexa Pharmaceuticals: Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study1.395CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune...
► Artikel lesen
BIODEXA PHARMACEUTICALS Aktie jetzt für 0€ handeln
13.06.Biodexa Pharmaceuticals ändert Nennwert der Aktien3
11.06.Biodexa-Aktionäre stimmen allen Beschlüssen auf Hauptversammlung zu-
11.06.Biodexa Pharmaceuticals PLC: Result of General Meeting68June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a...
► Artikel lesen
11.06.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer1
04.06.Biodexa Pharmaceuticals PLC: Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes137June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage...
► Artikel lesen
30.05.Biodexa Pharmaceuticals PLC: Shareholder Update463May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline...
► Artikel lesen
30.05.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer2
22.05.Biodexa Pharmaceuticals PLC (";Biodexa" or the "Company") Notice of General Meeting1
22.05.Biodexa sichert zusätzliche 3 Mio. US-Dollar für Krebsmedikamenten-Studie1
22.05.Biodexa secures additional $3M for cancer drug trial1
22.05.Biodexa Pharmaceuticals PLC: Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M148May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M...
► Artikel lesen
22.05.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer1
13.05.EC grants orphan drug status to Biodexa's oral FAP treatment1
12.05.Biodexa Pharmaceuticals: European Commission Grants Orphan Drug Designation For ERapa2
12.05.Biodexa gains orphan drug status in EU for colon disease treatment1
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1